Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative
Clinical Pharmacology & Therapeutics · 2026-08 · 120 (2) · 440-451
DOI: 10.1002/cpt.70310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 04.06.2026. Verfasst von Natalie Levy und 42 weiteren Autor:innen. Beteiligte Einrichtung: Aetion, Inc, New York, New York, USA. Hauptthemen laut MEDLINE: Randomized Controlled Trials as Topic, Research Design, Neoplasms, Medical Oncology. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amgen, AbbVie, Bayer.
Abstract (Originalsprache)
The Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative seeks to advance understanding of when real‐world data (RWD) can generate valid treatment effectiveness estimates by emulating completed oncology randomized controlled trials (RCTs). A prerequisite for meaningful RCT emulation insights is the identification and use of RWD with sufficient fitness to satisfy RCT‐specific data elements. We conducted a systematic, multi‐stage feasibility assessment of six commercially available US electronic health record‐based RWD sources across 23 candidate oncology RCTs. Each potential RCT‐RWD combination was first screened for availability of the RCT indication, outcomes, and sample size ≥ 1.5‐times enrollment for each trial arm. Combinations passing this screen underwent more detailed evaluation of RCT design elements including eligibility criteria, outcomes, and potential confounders. Each data element was rated with respect to availability, missingness, and validity. Final feasibility determination was informed by ratings of essential element capture and refined sample size estimates. Of 54 candidate RCT‐RWD combinations assessed, nine advanced to detailed feasibility assessment and three were selected for emulation protocol development. Fit‐for‐emulation constraints included complex eligibility criteria, biomarker requirements, performance status requirements, and outcome ascertainment. These findings highlight the importance of systematic feasibility evaluation before conducting emulations and may inform data selection for future RWD studies in oncology. Data fitness for oncology RCT emulation could be improved by linking high‐quality, oncology‐specific RWD sources to broader EHR and claims data sources or through customized data abstraction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Aetion, Inc, New York, New York, USA.
- COTA Healthcare, New York, New York, USA.
- Center for Observational Research, Amgen, San Francisco, California, USA.
- TriNetX, LLC, Cambridge, Massachusetts, USA.
- Tempus, Chicago, Illinois, USA.
- Reagan-Udall Foundation for the Food and Drug Administration, Washington, DC, USA.
ORCID-Profile: Natalie Levy, Paige Sheridan, Ulka Campbell, David Lenis, Inish O'Doherty, Adina Estrin, Nileesa Gautam, Monica Iyer, Gillis Carrigan, K Arnold Chan, Victoria Chia, Neil Dhopeshwarkar, Joy Eckert, Laura Fernandes, Joel Greshock, Rachele Hendricks-Sturrup, Sajan Khosla, Orsolya Lunacsek, Yanina Natanzon, Osayi Ovbiosa, Nelson Pace, Simone Pinheiro, Jennifer Rider, Mothaffar Fahed Rimawi, Carla Rodriguez-Watson, Chithra Sangli, Sebastian Schneeweiss, Mark Stewart, Aliki Taylor, Shirley Wang, Ann Madsen
Förderung
- Amgen
- AbbVie
- Bayer
- AstraZeneca
- Gilead Sciences
- Pfizer
- Johnson & Johnson
- Johnson and Johnson
Zitieren
APA
Levy, N., Sheridan, P., Campbell, U., Lenis, D., O'Doherty, I., Estrin, A., Gautam, N., Iyer, M., McDonald, S., Belli, A., Carrigan, G., Chan, K. A., Chen, J., Chia, V., Dhopeshwarkar, N., Eckert, J., Fernandes, L., Greshock, J., Hendricks-Sturrup, R., …, & Madsen, A. (2026). Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative. Clinical Pharmacology & Therapeutics, 120(2), 440-451. https://doi.org/10.1002/cpt.70310
Vancouver
Levy N, Sheridan P, Campbell U, Lenis D, O'Doherty I, Estrin A, et al. Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative. Clinical Pharmacology & Therapeutics. 2026;120(2):440-451. doi:10.1002/cpt.70310
BibTeX
@article{Levy2026,
author = {Levy, Natalie and Sheridan, Paige and Campbell, Ulka and Lenis, David and O'Doherty, Inish and Estrin, Adina and Gautam, Nileesa and Iyer, Monica and McDonald, Sarah and Belli, Andrew and Carrigan, Gillis and Chan, K Arnold and Chen, James and Chia, Victoria and Dhopeshwarkar, Neil and Eckert, Joy and Fernandes, Laura and Greshock, Joel and Hendricks-Sturrup, Rachele and Huang, Jenny and Jiao, XiaoLong and Khosla, Sajan and Lunacsek, Orsolya and McRoy, Lynn and Natanzon, Yanina and Ovbiosa, Osayi and Pace, Nelson and Pinheiro, Simone and Rees, Megan and Rider, Jennifer and Rimawi, Mothaffar Fahed and Robinson, Travis and Rodriguez-Watson, Carla and Sangli, Chithra and Sarsour, Khaled and Schneeweiss, Sebastian and Shapiro, Mark and Stewart, Mark and Taylor, Aliki and Wang, C K and Wang, Shirley and Zhang, Yiduo and Madsen, Ann},
title = {Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {120},
number = {2},
pages = {440--451},
doi = {10.1002/cpt.70310}
}
EUVIMED